These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34669648)

  • 21. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in
    Schoenfeld AJ; Chan JM; Kubota D; Sato H; Rizvi H; Daneshbod Y; Chang JC; Paik PK; Offin M; Arcila ME; Davare MA; Shinde U; Pe'er D; Rekhtman N; Kris MG; Somwar R; Riely GJ; Ladanyi M; Yu HA
    Clin Cancer Res; 2020 Jun; 26(11):2654-2663. PubMed ID: 31911548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
    Roper N; Brown AL; Wei JS; Pack S; Trindade C; Kim C; Restifo O; Gao S; Sindiri S; Mehrabadi F; El Meskini R; Ohler ZW; Maity TK; Venugopalan A; Cultraro CM; Akoth E; Padiernos E; Chen H; Kesarwala A; Smart DK; Nilubol N; Rajan A; Piotrowska Z; Xi L; Raffeld M; Panchenko AR; Sahinalp C; Hewitt S; Hoang CD; Khan J; Guha U
    Cell Rep Med; 2020 Apr; 1(1):. PubMed ID: 32483558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
    Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
    Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to trametinib in a nonsmall cell lung cancer patient with osimertinib resistance harboring GNAS R201C and R201H mutations: a case report.
    Lv Y; Zhou C; Chen Z; Zhao X; Sun Y; Li J; Gong Z; Zhang D; Huang H
    Anticancer Drugs; 2022 Oct; 33(9):966-969. PubMed ID: 35946511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
    Shah MP; Neal JW
    Drugs; 2022 Apr; 82(6):649-662. PubMed ID: 35412115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y; Saito Y; Yoshikawa T; Saito K; Nosaka K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S.
    Fanjat Y; Barazzutti H; Di Mauro I; Tabary-Martin L; Duranton-Tanneur V; Gimet S; Bérard H; Pedeutour F
    Cancer Genet; 2021 Aug; 256-257():158-161. PubMed ID: 34157597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer.
    Yi Y; Li P; Huang Y; Chen D; Fan S; Wang J; Yang M; Zeng S; Deng J; Lv X; Luo K; He Z; Liu H
    Oncogene; 2022 Sep; 41(37):4318-4329. PubMed ID: 35986102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review.
    Song Z; Ren G; Wang X; Du H; Sun Y; Hu L
    Ann Palliat Med; 2022 Mar; 11(3):1126-1134. PubMed ID: 35365043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
    Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.
    Yonesaka K; Kobayashi Y; Hayashi H; Chiba Y; Mitsudomi T; Nakagawa K
    Oncol Rep; 2019 Feb; 41(2):1059-1066. PubMed ID: 30483795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an
    Nishihara S; Yamaoka T; Ishikawa F; Ohmori T; Ando K; Kusumoto S; Kishino Y; Manabe R; Hasebe Y; Sagara H; Yoshida H; Tsurutani J
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
    Li S; Lin X; Sun S; Li S; Zhou C
    Anticancer Drugs; 2022 Oct; 33(9):963-965. PubMed ID: 36136993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.
    Zang H; Qian G; Arbiser J; Owonikoko TK; Ramalingam SS; Fan S; Sun SY
    Mol Oncol; 2020 Apr; 14(4):882-895. PubMed ID: 32003107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro.
    Nishino M; Suda K; Kobayashi Y; Ohara S; Fujino T; Koga T; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():149-155. PubMed ID: 30527179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.